THU TRAN: Open Payments
NPI 1255767844 · BILOXI, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,718 in 91 payments from 19 companies in 2025. Trend: 2023 $1,936 · 2024 $2,594 · 2025 $1,718
Food & beverage: $1,718
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. | 19 | $275 |
| AstraZeneca Pharmaceuticals LP | 11 | $208 |
| ABBVIE INC. | 12 | $202 |
| Janssen Biotech, Inc. | 8 | $184 |
| PFIZER INC. | 5 | $110 |
| Novartis Pharmaceuticals Corporation | 4 | $99 |
| GlaxoSmithKline, LLC. | 3 | $84 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $83 |
| ANI Pharmaceuticals, Inc. | 3 | $69 |
| Sumitomo Pharma America, Inc. | 4 | $69 |
Products named: TREMFYA, RINVOQ, COSENTYX, TAVNEOS, OTEZLA, BENLYSTA, CAPLYTA, XELJANZ.
Industry payments across MS — which companies pay providers there.
